18 months of development. ₹2 crore in funding. A product your customers actually love.

Then, three weeks after launch, a legal notice lands in your inbox. A competitor holds a patent on a core feature of your product one you had no idea existed. Now you’re choosing between a costly redesign, an expensive licensing deal, or pulling the product entirely.

This isn’t a hypothetical. It happens to startups and enterprises alike, and it’s one of the most expensive surprises in business. The worst part? It’s almost always preventable.

The Misconceptions That Cost Innovators

“Having a patent means I can sell my product.”

This is one of the most consequential misunderstandings in IP. A patent stops others from copying you; it says nothing about whether your own product infringes someone else’s earlier patent. These are entirely separate legal questions.

“We Googled it” isn’t an FTO search.

Patent claims are written in precise legal language. A product can infringe on an existing patent even when it looks nothing like the original invention. Without structured analysis, blind spots are guaranteed.

Doing it late is doing it wrong.

By launch time, your design, costs, and timeline are locked in. A blocking patent found now means expensive redesigns or worse, shelving the product entirely. FTO is a pre-launch exercise, not an afterthought.

What Freedom to Operate Actually Does?

An FTO analysis answers one critical question:

Can we commercialize this product without infringing anyone else’s active patent rights?

It maps the patent landscape in your technical domain, interprets whether existing claims read onto your product, and identifies where risks exist and how to navigate around them. The result: you move forward with informed confidence, not hope.

When It Goes Wrong: The Ranbaxy vs. Apotex Case

Few cases illustrate the stakes of FTO as clearly as Ranbaxy Pharmaceuticals, Inc. vs. Apotex, Inc.

The dispute centred on a patented process for manufacturing amorphous cefuroxime axetil, a broad-spectrum antibiotic. Apotex held a US patent (US5847118) covering this process using highly polar organic solvents, specifically sulfoxides, amides, and formic acid.

Ranbaxy, in manufacturing the same antibiotic, used acetic acid as the polar solvent, a substance Apotex had actually surrendered during patent prosecution. Apotex nonetheless asserted infringement under the Doctrine of Equivalents (DOE), arguing that acetic acid was functionally equivalent to the solvents it had claimed.

The courts disagreed. The Federal Circuit affirmed that prosecution history estoppel barred Apotex’s DOE claim because Apotex had submitted a narrowing amendment during prosecution and had explicitly surrendered solvents of similar polarity, including acetic acid. Ranbaxy’s process fell outside the enforceable scope of the patent.

The FTO lesson here is two-fold. For Ranbaxy, a thorough FTO analysis, including review of prosecution history, not just granted claims would have identified the surrendered scope early, de-risking the product well before litigation arose. For Apotex, the case is a reminder that amendments made during prosecution have lasting consequences for the enforceability of your own patent.

Understanding what a patent actually covers, and what it doesn’t, requires more than reading the claims on the face of the document.

What a Thorough FTO Analysis Covers

A credible FTO search goes well beyond a keyword search of patent databases. It includes:

• Patent Landscape Mapping: Identifying granted patents and pending applications in your technical domain across target jurisdictions.
• Claim Interpretation: Analyzing the specific language of claims, including amendments made during prosecution, to assess whether they cover your product.
• Infringement Risk Assessment: Determining which patents, if any, pose a genuine risk and at what degree.
• Expiry and Jurisdiction Check: Confirming whether identified patents are still in force, and in which countries. Expired patents no longer pose a threat; jurisdiction matters.
• Actionable Recommendations: Clear guidance on how to proceed: design around, seek a licence, challenge validity, or move forward with a calculated risk.

How PATHtoIP Approaches FTO

At PATHtoIP®, we treat Freedom to Operate as a strategic tool, not a compliance formality.

Our team of IP consultants, patent analysts, and technical experts works across sectors pharma, medtech, AI, cleantech, and more to identify the patents that actually matter for your product, including pending applications that could become problems down the line.

We meet you where you are: early-stage, pre-launch, or entering a new market.

The Question Isn’t Whether You Can Afford an FTO Search

It’s whether you can afford to skip it.

Reach out to us at info@pathtoip.com or visit www.pathtoip.com to learn how we can support your Freedom to Operate analysis.